2024-02-02 |
2024-02-01 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
15 000
-4.0%
15,29
229 386 USD
|
15 000
-4.0%
|
15,29
|
229 386 USD
|
|
2024-01-04 |
2024-01-02 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
15 000
-5.4%
15,67
235 088 USD
|
15 000
-5.4%
|
15,67
|
235 088 USD
|
|
2023-12-22 |
2023-12-21 |
V
Vente
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
40 000
-13.3%
15,43
617 060 USD
|
40 000
-13.3%
|
15,43
|
617 060 USD
|
|
2023-12-22 |
2023-12-21 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
50 000
-14.3%
15,44
772 220 USD
|
50 000
-14.3%
|
15,44
|
772 220 USD
|
|
2023-12-22 |
2023-12-20 |
VP
Vente planifiée
|
Kanesa-thasan Niranjan
Chief Medical Officer
Dirigeant
|
11 884
-5.0%
15,46
183 692 USD
|
11 884
-5.0%
|
15,46
|
183 692 USD
|
|
2023-12-22 |
2023-12-20 |
V
Vente
|
Russo Thomas Joseph
Chief Financial Officer
Dirigeant
|
4 430
-10.4%
15,47
68 510 USD
|
4 430
-10.4%
|
15,47
|
68 510 USD
|
|
2023-12-22 |
2023-12-20 |
VP
Vente planifiée
|
Russo Thomas Joseph
Chief Financial Officer
Dirigeant
|
10 753
-20.2%
15,46
166 210 USD
|
10 753
-20.2%
|
15,46
|
166 210 USD
|
|
2023-12-22 |
2023-12-20 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
62 205
-25.2%
15,46
961 509 USD
|
62 205
-25.2%
|
15,46
|
961 509 USD
|
|
2023-12-22 |
2023-12-20 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
7 934
-5.7%
15,46
122 637 USD
|
7 934
-5.7%
|
15,46
|
122 637 USD
|
|
2023-12-15 |
2023-12-13 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
8 759
-6.3%
16,01
140 190 USD
|
8 759
-6.3%
|
16,01
|
140 190 USD
|
|
2023-08-01 |
2023-07-31 |
VP
Vente planifiée
|
Russo Thomas Joseph
Chief Financial Officer
Dirigeant
|
3 066
-6.3%
8,86
27 169 USD
|
3 066
-6.3%
|
8,86
|
27 169 USD
|
|
2023-08-01 |
2023-07-31 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
11 788
-4.6%
8,86
104 459 USD
|
11 788
-4.6%
|
8,86
|
104 459 USD
|
|
2023-08-01 |
2023-07-31 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
1 888
-1.3%
8,86
16 731 USD
|
1 888
-1.3%
|
8,86
|
16 731 USD
|
|
2023-08-01 |
2023-07-31 |
VP
Vente planifiée
|
Kanesa-thasan Niranjan
Chief Medical Officer
Dirigeant
|
3 323
-1.4%
8,86
29 447 USD
|
3 323
-1.4%
|
8,86
|
29 447 USD
|
|
2023-07-03 |
2023-07-03 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
2 095
-0.7%
9,59
20 083 USD
|
2 095
-0.7%
|
9,59
|
20 083 USD
|
|
2023-07-03 |
2023-07-03 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
14 261
-4.7%
8,74
124 660 USD
|
14 261
-4.7%
|
8,74
|
124 660 USD
|
|
2023-05-25 |
2023-05-23 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
10 000
-6.6%
10,00
100 000 USD
|
10 000
-6.6%
|
10,00
|
100 000 USD
|
|
2023-04-05 |
2023-04-03 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
300
-0.1%
6,56
1 968 USD
|
300
-0.1%
|
6,56
|
1 968 USD
|
|
2023-04-05 |
2023-04-03 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
20 143
-6.5%
6,08
122 439 USD
|
20 143
-6.5%
|
6,08
|
122 439 USD
|
|
2023-03-08 |
2023-03-06 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
5 000
-3.2%
7,75
38 737 USD
|
5 000
-3.2%
|
7,75
|
38 737 USD
|
|
2023-02-15 |
2023-02-14 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
3 349
-1.1%
10,17
34 064 USD
|
3 349
-1.1%
|
10,17
|
34 064 USD
|
|
2023-02-15 |
2023-02-13 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
1 522
-0.5%
10,69
16 274 USD
|
1 522
-0.5%
|
10,69
|
16 274 USD
|
|
2023-02-15 |
2023-02-13 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
7 506
-3.0%
10,69
80 259 USD
|
7 506
-3.0%
|
10,69
|
80 259 USD
|
|
2023-02-15 |
2023-02-13 |
VP
Vente planifiée
|
Russo Thomas Joseph
Chief Financial Officer
Dirigeant
|
1 902
-3.8%
10,69
20 337 USD
|
1 902
-3.8%
|
10,69
|
20 337 USD
|
|
2023-02-15 |
2023-02-13 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
1 660
-1.0%
10,69
17 750 USD
|
1 660
-1.0%
|
10,69
|
17 750 USD
|
|
2023-02-15 |
2023-02-13 |
VP
Vente planifiée
|
Bekiroglu Elizabeth
General Counsel & Corp. Sec.
Dirigeant
|
5 922
-5.4%
10,69
63 322 USD
|
5 922
-5.4%
|
10,69
|
63 322 USD
|
|
2023-02-15 |
2023-02-13 |
VP
Vente planifiée
|
Kanesa-thasan Niranjan
Chief Medical Officer
Dirigeant
|
1 794
-0.7%
10,69
19 183 USD
|
1 794
-0.7%
|
10,69
|
19 183 USD
|
|
2024-01-05 |
2023-01-04 |
V
Vente
|
Kanesa-thasan Niranjan
Chief Medical Officer
Dirigeant
|
106 373
-32.2%
15,70
1 670 460 USD
|
106 373
-32.2%
|
15,70
|
1 670 460 USD
|
|
2022-12-23 |
2022-12-21 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
66 764
-22.9%
8,96
598 406 USD
|
66 764
-22.9%
|
8,96
|
598 406 USD
|
|
2022-12-16 |
2022-12-15 |
V
Vente
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
19 648
-87.6%
11,14
218 963 USD
|
19 648
-87.6%
|
11,14
|
218 963 USD
|
|
2022-09-09 |
2022-09-08 |
VP
Vente planifiée
|
Bekiroglu Elizabeth
General Counsel & Corp. Sec.
Dirigeant
|
1 813
-1.6%
4,87
8 835 USD
|
1 813
-1.6%
|
4,87
|
8 835 USD
|
|
2022-08-02 |
2022-08-02 |
VP
Vente planifiée
|
Russo Thomas Joseph
Chief Financial Officer
Dirigeant
|
495
-1.0%
6,70
3 318 USD
|
495
-1.0%
|
6,70
|
3 318 USD
|
|
2022-08-02 |
2022-08-02 |
VP
Vente planifiée
|
Richardson Charles E
SVP, Technical Operations
Dirigeant
|
371
-0.2%
6,70
2 487 USD
|
371
-0.2%
|
6,70
|
2 487 USD
|
|
2022-08-02 |
2022-08-02 |
VP
Vente planifiée
|
Kanesa-thasan Niranjan
Chief Medical Officer
Dirigeant
|
543
-0.2%
6,70
3 640 USD
|
543
-0.2%
|
6,70
|
3 640 USD
|
|
2022-08-02 |
2022-08-02 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
1 904
-0.6%
6,70
12 764 USD
|
1 904
-0.6%
|
6,70
|
12 764 USD
|
|
2022-08-02 |
2022-08-02 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
303
-0.2%
6,70
2 031 USD
|
303
-0.2%
|
6,70
|
2 031 USD
|
|
2022-08-02 |
2022-08-02 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
453
-0.2%
6,70
3 037 USD
|
453
-0.2%
|
6,70
|
3 037 USD
|
|
2022-08-02 |
2022-08-01 |
VP
Vente planifiée
|
Russo Thomas Joseph
Chief Financial Officer
Dirigeant
|
1 825
-3.6%
6,64
12 113 USD
|
1 825
-3.6%
|
6,64
|
12 113 USD
|
|
2022-08-02 |
2022-08-01 |
VP
Vente planifiée
|
Richardson Charles E
SVP, Technical Operations
Dirigeant
|
1 368
-0.8%
6,64
9 080 USD
|
1 368
-0.8%
|
6,64
|
9 080 USD
|
|
2022-08-02 |
2022-08-01 |
VP
Vente planifiée
|
Kanesa-thasan Niranjan
Chief Medical Officer
Dirigeant
|
2 001
-0.8%
6,64
13 281 USD
|
2 001
-0.8%
|
6,64
|
13 281 USD
|
|
2022-08-02 |
2022-08-01 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
7 017
-2.3%
6,64
46 575 USD
|
7 017
-2.3%
|
6,64
|
46 575 USD
|
|
2022-08-02 |
2022-08-01 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
1 118
-0.8%
6,64
7 421 USD
|
1 118
-0.8%
|
6,64
|
7 421 USD
|
|
2022-08-02 |
2022-08-01 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
9 337
-3.1%
6,64
61 973 USD
|
9 337
-3.1%
|
6,64
|
61 973 USD
|
|
2022-08-02 |
2022-07-29 |
VP
Vente planifiée
|
Russo Thomas Joseph
Chief Financial Officer
Dirigeant
|
639
-1.2%
7,11
4 542 USD
|
639
-1.2%
|
7,11
|
4 542 USD
|
|
2022-08-02 |
2022-07-29 |
VP
Vente planifiée
|
Richardson Charles E
SVP, Technical Operations
Dirigeant
|
479
-0.3%
7,11
3 405 USD
|
479
-0.3%
|
7,11
|
3 405 USD
|
|
2022-08-02 |
2022-07-29 |
VP
Vente planifiée
|
Kanesa-thasan Niranjan
Chief Medical Officer
Dirigeant
|
701
-0.3%
7,11
4 982 USD
|
701
-0.3%
|
7,11
|
4 982 USD
|
|
2022-08-02 |
2022-07-29 |
VP
Vente planifiée
|
Simpson Adam K.
Chief Executive Officer
Administrateur exécutif
|
2 456
-0.8%
7,11
17 456 USD
|
2 456
-0.8%
|
7,11
|
17 456 USD
|
|
2022-08-02 |
2022-07-29 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
391
-0.3%
7,11
2 779 USD
|
391
-0.3%
|
7,11
|
2 779 USD
|
|
2022-08-02 |
2022-07-29 |
VP
Vente planifiée
|
Holtzman Douglas
Chief Scientific Officer
Dirigeant
|
585
-0.2%
7,11
4 158 USD
|
585
-0.2%
|
7,11
|
4 158 USD
|
|
2022-04-05 |
2022-04-01 |
A
Achat
|
MCDADE MARK
Administrateur non-exécutif
|
42 225
+526.6%
7,10
299 798 USD
|
42 225
+526.6%
|
7,10
|
299 798 USD
|
|
2022-03-30 |
2022-03-29 |
A
Achat
|
RA CAPITAL MANAGEMENT, L.P.
Administrateur non-exécutif
Actionnaire important
|
8 900
+0.1%
4,75
42 271 USD
|
8 900
+0.1%
|
4,75
|
42 271 USD
|
|
2022-03-30 |
2022-03-28 |
A
Achat
|
RA CAPITAL MANAGEMENT, L.P.
Administrateur non-exécutif
Actionnaire important
|
175 318
+3.0%
4,53
794 611 USD
|
175 318
+3.0%
|
4,53
|
794 611 USD
|
|
2022-03-09 |
2022-03-07 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
484
-0.5%
17,81
8 620 USD
|
484
-0.5%
|
17,81
|
8 620 USD
|
|
2022-03-09 |
2022-03-07 |
VP
Vente planifiée
|
Cearley Cassia
Chief Business Officer
Dirigeant
|
9 516
-8.8%
17,13
163 009 USD
|
9 516
-8.8%
|
17,13
|
163 009 USD
|
|
2021-08-03 |
2021-08-02 |
A
Achat
|
Gould Terry P
Administrateur non-exécutif
|
12 368
+5.1%
15,00
185 520 USD
|
12 368
+5.1%
|
15,00
|
185 520 USD
|
|
2021-08-03 |
2021-08-02 |
A
Achat
|
Gould Terry P
Administrateur non-exécutif
|
26 604
+5.1%
15,00
399 060 USD
|
26 604
+5.1%
|
15,00
|
399 060 USD
|
|
2021-08-03 |
2021-08-02 |
A
Achat
|
Gould Terry P
Administrateur non-exécutif
|
46 381
+5.1%
15,00
695 715 USD
|
46 381
+5.1%
|
15,00
|
695 715 USD
|
|
2021-08-03 |
2021-08-02 |
A
Achat
|
Gould Terry P
Administrateur non-exécutif
|
47 981
+5.1%
15,00
719 715 USD
|
47 981
+5.1%
|
15,00
|
719 715 USD
|
|
2021-08-02 |
2021-08-02 |
A
Achat
|
Sanofi
Actionnaire important
|
66 667
+2.2%
15,00
1 000 005 USD
|
66 667
+2.2%
|
15,00
|
1 000 005 USD
|
|